ASL perfusion imaging

Developing imaging biomarkers for Alzheimer’s dementia

Mediri leads the internationally funded research project ASPIRE with the aim to develop non-invasive biomarkers for early recognition of demential diseases. The mTRIAL ASPIRE analysis tool is readily available as cost-efficient secondary endpoint in clinical trials, ultimatively aiming to support patient-specific diagnosis.
Click here for mTRIAL demo version

Professional image analysis with a focus on usability

Analysis software for the non-invasive perfusion imaging technique Arterial Spin Labeling (ASL) is integrated in our professional solution “mTRIAL”, to support clinical researchers to conduct research and clinical trials in real-time. Current highlights are the new web-based DICOM viewer and the atlas based regional perfusion analysis, allowing automated analysis of longitudinal studies. Contact us if you want to learn more about brain perfusion analysis with ASL for clinical studies.

Our great project partners:

Goldstandardphantoms Ltd, established in London, UK, builds highest accuracy perfusion phantoms used for quality control, ensuring stable and reliable image quantification in clinical trials.

The Amsterdam University Medical Center in the Netherlands is at the forefront of clinical research in Alzheimer’s and dementia diseases. They boost the ASL community research by contributing their knowledge to the analysis tool “ExploreASL”.

The University of Applied Sciences Darmstadt, Germany, has a strong focus on computer vision technologies. They provide the AI for AIzheimer’s prediction based on the most advanced neural networks.

Web-based interactive DICOM viewer

for instant display of evaluation results – anytime, anywhere.

ASL evaluation report

Our focus lies on a user-friendly display of ASL evaluation results to support efficient study workflows and reliable results. We provide interactive reports for quick overview of a participant as well as pdf reports for structured archiving.

« ASL has the potential to improve diagnosis and treatment monitoring in Alzheimer’s Disease, especially for older adults with cardiovascular risk factors. »

Dr. Henk-Jan Mutsaerts,
Assistant Professor,
Amsterdam UMC